Symbol="KZR"
AssetType="Common Stock"
Name="Kezar Life Sciences Inc"
Description="Kezar Life Sciences, Inc., a clinical-stage biotechnology company, is dedicated to the discovery and development of new small molecule therapies to address the unmet needs in immune-mediated diseases and cancer in the United States. The company is headquartered in South San Francisco, California."
CIK="1645666"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="159296000"
EBITDA="-78943000"
PERatio="None"
PEGRatio="None"
BookValue="3.565"
DividendPerShare="0"
DividendYield="0"
EPS="-0.98"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.186"
ReturnOnEquityTTM="-0.307"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.98"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="15.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.688"
EVToRevenue="-"
EVToEBITDA="-3.262"
Beta="0.129"
num_52WeekHigh="10.81"
num_52WeekLow="2.13"
num_50DayMovingAverage="2.554"
num_200DayMovingAverage="4.92"
SharesOutstanding="72407000"
DividendDate="None"
ExDividendDate="None"
symbol="KZR"
open="2.15"
high="2.25"
low="2.15"
price="2.20"
volume="330431.00"
latest_trading_day="2023-07-28"
previous_close="2.14"
change="0.06"
change_percent="2.8037%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="970078"
Change_recent_avg="-0.04"
Delta_recent_avg="0.21"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-1.19"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="1135"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0168.jpeg"
image_negative_thumbnail_id_2="122"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0054.jpeg"
image_neutral_thumbnail_id_1="586"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0013.jpeg"
image_neutral_thumbnail_id_2="593"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0006.jpeg"
image_positive_thumbnail_id_1="995"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0157.jpeg"
image_positive_thumbnail_id_2="607"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0101.jpeg"
image_professor_thumbnail_id_1="1200"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0034.jpeg"
image_professor_thumbnail_id_2="1197"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0031.jpeg"
